Neuronetics Crescita futura
Criteri Future verificati 0/6
Si prevede che Neuronetics aumenterà gli utili e i ricavi rispettivamente del 12.6% e 9.4% all'anno, mentre si prevede che l'EPS crescerà del 15.7% all'anno.
Informazioni chiave
12.6%
Tasso di crescita degli utili
15.67%
Tasso di crescita dell'EPS
| Medical Equipment crescita degli utili | 16.2% |
| Tasso di crescita dei ricavi | 9.4% |
| Rendimento futuro del capitale proprio | n/a |
| Copertura analitica | Low |
| Ultimo aggiornamento | 12 May 2026 |
Aggiornamenti recenti sulla crescita futura
Articolo di analisi • Nov 06
The Neuronetics, Inc. (NASDAQ:STIM) Third-Quarter Results Are Out And Analysts Have Published New Forecasts
Neuronetics, Inc. ( NASDAQ:STIM ) last week reported its latest third-quarter results, which makes it a good time for...Articolo di analisi • Aug 07
Here's What Analysts Are Forecasting For Neuronetics, Inc. (NASDAQ:STIM) After Its Second-Quarter Results
NasdaqGM:STIM 1 Year Share Price vs Fair Value Explore Neuronetics's Fair Values from the Community and select yours...Recent updates
Aggiornamento della narrazione • May 01
STIM: Recalibrated Assumptions And Policy Tailwinds Will Drive Future Repricing
Analysts have trimmed their price target on Neuronetics by $4 to reflect updated assumptions on discount rates, profit margins, and future P/E expectations. This results in a slightly lower fair value outlook while keeping the core narrative largely intact.Aggiornamento della narrazione • Apr 16
STIM: Reset Expectations And Higher Discount Rate Will Support Future Repricing
Analysts have lowered their price target on Neuronetics by $4, reflecting updated views on the discount rate, profit margin assumptions, and future P/E levels. Analyst Commentary Bullish Takeaways Bullish analysts view the revised price target as closer to their current assumptions on discount rates and future P/E levels, which they see as a more grounded reflection of Neuronetics' risk profile.
Nuova narrazione • Apr 04
Clinic Margin Pressures And Cash Burn Will Shape This Mental Health Platform’s Eventual Upside
Catalysts About Neuronetics Neuronetics develops and operates NeuroStar TMS systems and Greenbrook mental health clinics that provide device based and drug based treatments for depression and other conditions. What are the underlying business or industry changes driving this perspective?Aggiornamento della narrazione • Apr 02
STIM: Updated Discount Rate Assumptions Will Support Bullish Repricing Over Time
Analysts have trimmed their price target on Neuronetics by $4 to reflect updated assumptions on discount rates, margins, and future P/E. This has led to a slightly more cautious outlook on the shares.
Nuova narrazione • Mar 18
Clinic Network And New Therapies Will Transform Mental Health Treatment Over The Next Decade
Catalysts About Neuronetics Neuronetics develops and commercializes NeuroStar TMS systems and operates Greenbrook clinics that provide device based and drug treatments for mental health conditions, including treatment resistant depression. What are the underlying business or industry changes driving this perspective?Aggiornamento della narrazione • Mar 18
STIM: Leadership Transition And 2026 Revenue Outlook Will Support Bullish Repricing
Analysts have cut their price target on Neuronetics to $4.33 from $6.50, citing updated assumptions for lower revenue growth at 12.65%, a higher discount rate of 10.04%, a slightly higher profit margin of 13.36%, and a reduced future P/E of 16.22x. What's in the News Neuronetics plans a leadership transition with Dan Reuvers appointed as the next Chief Executive Officer, effective March 23, 2026, while current CEO Keith Sullivan is scheduled to step down on March 23, 2026 and retire on March 31, 2026 after roughly five and a half years leading the company (Key Developments).Articolo di analisi • Jan 07
There's No Escaping Neuronetics, Inc.'s (NASDAQ:STIM) Muted Revenues Despite A 25% Share Price Rise
Neuronetics, Inc. ( NASDAQ:STIM ) shareholders are no doubt pleased to see that the share price has bounced 25% in the...Articolo di analisi • Dec 13
Would Neuronetics (NASDAQ:STIM) Be Better Off With Less Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Articolo di analisi • Nov 14
Slammed 29% Neuronetics, Inc. (NASDAQ:STIM) Screens Well Here But There Might Be A Catch
To the annoyance of some shareholders, Neuronetics, Inc. ( NASDAQ:STIM ) shares are down a considerable 29% in the last...Articolo di analisi • Nov 06
The Neuronetics, Inc. (NASDAQ:STIM) Third-Quarter Results Are Out And Analysts Have Published New Forecasts
Neuronetics, Inc. ( NASDAQ:STIM ) last week reported its latest third-quarter results, which makes it a good time for...Articolo di analisi • Aug 26
Market Cool On Neuronetics, Inc.'s (NASDAQ:STIM) Revenues Pushing Shares 29% Lower
Neuronetics, Inc. ( NASDAQ:STIM ) shares have had a horrible month, losing 29% after a relatively good period...Articolo di analisi • Aug 07
Here's What Analysts Are Forecasting For Neuronetics, Inc. (NASDAQ:STIM) After Its Second-Quarter Results
NasdaqGM:STIM 1 Year Share Price vs Fair Value Explore Neuronetics's Fair Values from the Community and select yours...Articolo di analisi • May 15
Why We Think Neuronetics, Inc.'s (NASDAQ:STIM) CEO Compensation Is Not Excessive At All
Key Insights Neuronetics' Annual General Meeting to take place on 22nd of May Total pay for CEO Keith Sullivan includes...Articolo di analisi • May 09
Neuronetics, Inc. (NASDAQ:STIM) Just Reported And Analysts Have Been Lifting Their Price Targets
It's been a good week for Neuronetics, Inc. ( NASDAQ:STIM ) shareholders, because the company has just released its...Articolo di analisi • May 04
Neuronetics, Inc.'s (NASDAQ:STIM) 30% Jump Shows Its Popularity With Investors
Neuronetics, Inc. ( NASDAQ:STIM ) shares have continued their recent momentum with a 30% gain in the last month alone...
Nuova narrazione • Apr 09
TMS Acquisition And BMP Expansion Will Transform Treatment Delivery
The acquisition of Greenbrook and expansion of the BMP program are expected to significantly boost revenue through increased patient access and operational efficiency.Seeking Alpha • Mar 30
Neuronetics: Explosive Growth Poised To Soar On FDA Breakthroughs
Summary Neuronetics has shown significant growth, with a 430% rally since November and strong Q4 2024 results, driven by its NeuroStar TMS therapy system. The company's valuation remains attractive despite recent gains, with a forward P/S ratio of 1.71x, well below sector norms, indicating potential undervaluation. Strategic acquisitions, including Greenbrook, and FDA approvals are expected to drive revenue growth and cash flow positivity by Q3 2025. Despite risks like high volatility and competition, Neuronetics' strong market position and growth potential make it a promising investment. Read the full article on Seeking AlphaArticolo di analisi • Mar 06
Neuronetics, Inc.'s (NASDAQ:STIM) Shares Leap 69% Yet They're Still Not Telling The Full Story
Despite an already strong run, Neuronetics, Inc. ( NASDAQ:STIM ) shares have been powering on, with a gain of 69% in...Articolo di analisi • Feb 10
Industry Analysts Just Made A Dazzling Upgrade To Their Neuronetics, Inc. (NASDAQ:STIM) Revenue Forecasts
Shareholders in Neuronetics, Inc. ( NASDAQ:STIM ) may be thrilled to learn that the analysts have just delivered a...Articolo di analisi • Jan 11
Neuronetics, Inc.'s (NASDAQ:STIM) Shares Leap 43% Yet They're Still Not Telling The Full Story
Despite an already strong run, Neuronetics, Inc. ( NASDAQ:STIM ) shares have been powering on, with a gain of 43% in...Articolo di analisi • Jan 02
Neuronetics (NASDAQ:STIM) Is Making Moderate Use Of Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Articolo di analisi • Nov 18
Neuronetics, Inc. (NASDAQ:STIM) Analysts Just Slashed Next Year's Revenue Estimates By 12%
Market forces rained on the parade of Neuronetics, Inc. ( NASDAQ:STIM ) shareholders today, when the analysts...Articolo di analisi • Nov 05
A Piece Of The Puzzle Missing From Neuronetics, Inc.'s (NASDAQ:STIM) 28% Share Price Climb
Those holding Neuronetics, Inc. ( NASDAQ:STIM ) shares would be relieved that the share price has rebounded 28% in the...Articolo di analisi • Aug 13
Investors Give Neuronetics, Inc. (NASDAQ:STIM) Shares A 60% Hiding
The Neuronetics, Inc. ( NASDAQ:STIM ) share price has fared very poorly over the last month, falling by a substantial...Articolo di analisi • May 24
Here's Why Shareholders May Want To Be Cautious With Increasing Neuronetics, Inc.'s (NASDAQ:STIM) CEO Pay Packet
Key Insights Neuronetics will host its Annual General Meeting on 30th of May Total pay for CEO Keith Sullivan includes...Articolo di analisi • May 09
The Neuronetics, Inc. (NASDAQ:STIM) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Shareholders in Neuronetics, Inc. ( NASDAQ:STIM ) had a terrible week, as shares crashed 28% to US$2.55 in the week...Seeking Alpha • May 09
Neuronetics: Reality Set In
Summary Neuronetics' share price dropped after reporting soft Q1 2024 results, with weak system sales undermining strong treatment demand. Neuronetics' losses remain relatively large, and the company's balance sheet provides it with limited flexibility. The stock may have further to fall if Neuronetics is not able to demonstrate a clear path to profitability in the coming quarters. Read the full article on Seeking AlphaArticolo di analisi • May 08
Market Cool On Neuronetics, Inc.'s (NASDAQ:STIM) Revenues Pushing Shares 36% Lower
Neuronetics, Inc. ( NASDAQ:STIM ) shareholders won't be pleased to see that the share price has had a very rough month...Articolo di analisi • May 01
Neuronetics (NASDAQ:STIM) Has Debt But No Earnings; Should You Worry?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Articolo di analisi • Mar 17
Even With A 26% Surge, Cautious Investors Are Not Rewarding Neuronetics, Inc.'s (NASDAQ:STIM) Performance Completely
Despite an already strong run, Neuronetics, Inc. ( NASDAQ:STIM ) shares have been powering on, with a gain of 26% in...Seeking Alpha • Jan 30
Neuronetics: Modest Improvements Are Not Enough
Summary Neuronetics' stock has rebounded significantly over the past 3 months, although this has been driven more by investor sentiment than company fundamentals. TMS remains underutilized given its efficacy, which should lead to greater adoption in coming years, even if growth is at a relatively modest pace. STIM is still a long way from profitability. Something the company must rectify in the coming quarters. Modest growth and a gradual improvement in profitability will probably not be sufficient to lift the share price higher. Read the full article on Seeking AlphaArticolo di analisi • Dec 19
Neuronetics, Inc. (NASDAQ:STIM) Soars 61% But It's A Story Of Risk Vs Reward
The Neuronetics, Inc. ( NASDAQ:STIM ) share price has done very well over the last month, posting an excellent gain of...Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Utili | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 12/31/2028 | 198 | -22 | N/A | N/A | 1 |
| 12/31/2027 | 178 | -26 | N/A | N/A | 3 |
| 12/31/2026 | 161 | -33 | N/A | N/A | 3 |
| 3/31/2026 | 152 | -37 | -14 | -13 | N/A |
| 12/31/2025 | 149 | -39 | -21 | -20 | N/A |
| 9/30/2025 | 130 | -45 | -31 | -30 | N/A |
| 6/30/2025 | 111 | -49 | -35 | -35 | N/A |
| 3/31/2025 | 89 | -49 | -37 | -36 | N/A |
| 12/31/2024 | 75 | -44 | -32 | -31 | N/A |
| 9/30/2024 | 73 | -36 | -23 | -20 | N/A |
| 6/30/2024 | 72 | -32 | -27 | -25 | N/A |
| 3/31/2024 | 73 | -28 | -31 | -29 | N/A |
| 12/31/2023 | 71 | -30 | -34 | -32 | N/A |
| 9/30/2023 | 69 | -33 | -39 | -37 | N/A |
| 6/30/2023 | 68 | -31 | -36 | -34 | N/A |
| 3/31/2023 | 67 | -37 | -36 | -34 | N/A |
| 12/31/2022 | 65 | -37 | -34 | -31 | N/A |
| 9/30/2022 | 62 | -37 | -36 | -32 | N/A |
| 6/30/2022 | 59 | -37 | -37 | -34 | N/A |
| 3/31/2022 | 57 | -34 | -34 | -31 | N/A |
| 12/31/2021 | 55 | -31 | -30 | -28 | N/A |
| 9/30/2021 | 56 | -27 | -27 | -25 | N/A |
| 6/30/2021 | 55 | -22 | -22 | -20 | N/A |
| 3/31/2021 | 50 | -23 | -25 | -24 | N/A |
| 12/31/2020 | 49 | -27 | -29 | -28 | N/A |
| 9/30/2020 | 51 | -31 | -34 | -33 | N/A |
| 6/30/2020 | 55 | -35 | -38 | -37 | N/A |
| 3/31/2020 | 61 | -34 | -35 | -35 | N/A |
| 12/31/2019 | 63 | -29 | N/A | -30 | N/A |
| 9/30/2019 | 61 | -28 | N/A | -26 | N/A |
| 6/30/2019 | 59 | -26 | N/A | -24 | N/A |
| 3/31/2019 | 55 | -26 | N/A | -22 | N/A |
| 12/31/2018 | 53 | -24 | N/A | -21 | N/A |
| 9/30/2018 | 49 | -23 | N/A | -18 | N/A |
| 6/30/2018 | 46 | -22 | N/A | -15 | N/A |
| 3/31/2018 | 43 | -17 | N/A | -13 | N/A |
| 12/31/2017 | 40 | -16 | N/A | -11 | N/A |
| 12/31/2016 | 34 | -11 | N/A | -9 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: Si prevede che STIM rimarrà non redditizia nei prossimi 3 anni.
Guadagni vs Mercato: Si prevede che STIM rimarrà non redditizia nei prossimi 3 anni.
Guadagni ad alta crescita: Si prevede che STIM rimarrà non redditizia nei prossimi 3 anni.
Ricavi vs Mercato: Si prevede che il fatturato di STIM ( 9.4% all'anno) crescerà più lentamente rispetto al mercato US ( 11.7% all'anno).
Ricavi ad alta crescita: Si prevede che il fatturato di STIM ( 9.4% all'anno) crescerà più lentamente di 20% all'anno.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Dati insufficienti per determinare se il Return on Equity di STIM è previsto essere elevato tra 3 anni
Scoprire le aziende in crescita
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/15 07:20 |
| Prezzo dell'azione a fine giornata | 2026/05/15 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Neuronetics, Inc. è coperta da 3 analisti. 3 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| William Plovanic | Canaccord Genuity |
| Daniel Stauder | Citizens JMP Securities, LLC |
| Adam Maeder | Piper Sandler Companies |